Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial
Biotech
Neuphoria nixes social anxiety program after phase 3 flop
Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.
Gabrielle Masson
Oct 21, 2025 10:44am
2 ex-Moderna leaders unveil $325M inaugural VC fund
Oct 9, 2025 3:09pm
Sarepta faces new scrutiny after 3rd patient death
Jul 18, 2025 10:19am
FDA debuts priority review voucher with 2-month timeline goal
Jun 17, 2025 11:59am
US biotechs must adapt as global competition rises: Antares CEO
Jun 17, 2025 8:15am
China proposal would match US clinical trial review times
Jun 16, 2025 5:30pm
